Last edition
News about "Conditional Marketing Authorisation (CMA)"
MaaT Pharma Updates Marketing Authorisation Application for MaaT013 in Acute GvHD Treatment
MaaT Pharma reports a negative trend opinion from the EMA’s CHMP for the marketing authorisation application of MaaT013 in acute Graft-Versus-Host Disease (aGVHD), with plans to seek re-examination following the formal June CHMP vote.
Conditional Marketing Authorisation (CMA) | 21/05/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members